Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Amy S PallerCarsten FlohrLawrence F EichenfieldAlan D IrvineJamie WeismanJennifer SoungAna Pinto CorreiaChitra R NatalieClaudia Rodriguez CaprilesEvangeline PierceSarah ReifeisRenata Gontijo LimaClara Armengol TubauVivian LaquerStephan WeidingerPublished in: Dermatology and therapy (2023)
ClinicalTrials.gov identifier, NCT04250350.